Advent Life Sciences is a venture capital and private equity firm investing in life science technology companies that is headquartered in London, England and was founded in 2010. The firm typically invests in life science companies in the United Kingdom, Europe, and the United States. Sectors of the life science industry that Advent Life Sciences invests in are new drug discovery, enabling technologies, medical technologies, and medical diagnostics.
Notable investments made by Advent Life Sciences include: Algeta, Avila, Biocartis, CardiacAssist, CardiAQ Valve Technologies, CardioKine, Callnovo, CN Creative, Conatus Pharmaceuticals, EUSA Pharma, KuDos Pharmaceuticals, Micromet, PowderMed, RespiVert, Santarus, Speciality European Pharma, Thiakis, and UniQure.
On October 28, 2014 Advent Life Sciences announced raising $235 million for their second venture capital fund for backing early and mid-stage life science companies. Raj Parek, a general partner at Advent Life Sciences, made the following statement regarding the firms second fund:
We thank our returning and new LPs for the strength of their support, which allowed us to raise the commitments for this Fund in a matter of weeks. The interest from LPs and demand for the Fund, particularly in current markets, is in large part a recognition of the scientific and medical entrepreneurs, CEOs and Management teams whose commitment, vision and energy is enabling our portfolio companies to bring important medical innovations to patients. It is a privilege to work with them.
Documentaries, videos and podcasts